| (Values in U.S. Thousands) | Aug, 2023 | Aug, 2022 | Aug, 2021 | Aug, 2020 | Aug, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -5,267 | -7,495 | -8,255 | -423 | 0 |
| Net Income Growth | +29.73% | +9.20% | -1,853.24% | unch | unch |
Tryp Therapeutics Inc (TRYP.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Tryp Therapeutics Inc is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, for the treatment of diseases with unmet medical needs. Tryp's program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The company operates in two reportable segments; the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in the United States.
Fiscal Year End Date: 08/31